{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(6)"],"submitter":["Espinosa-Rodriguez BA"],"pubmed_abstract":["Metabolic reprogramming in cancer is considered to be one of the most important hallmarks to drive proliferation, angiogenesis, and invasion. AMP-activated protein kinase activation is one of the established mechanisms for metformin's anti-cancer actions. However, it has been suggested that metformin may exert antitumoral effects by the modulation of other master regulators of cellular energy. Here, based on structural and physicochemical criteria, we tested the hypothesis that metformin may act as an antagonist of L-arginine metabolism and other related metabolic pathways. First, we created a database containing different L-arginine-related metabolites and biguanides. After that, comparisons of structural and physicochemical properties were performed employing different cheminformatic too"],"journal":["International journal of molecular sciences"],"pagination":["5316"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10049129"],"repository":["biostudies-literature"],"pubmed_title":["Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study."],"pmcid":["PMC10049129"],"pubmed_authors":["Ramirez-Cabrera MA","Balderas-Renteria I","Arredondo-Espinoza EU","Carranza-Rosales P","Trevino-Almaguer D","Espinosa-Rodriguez BA","Mendez-Lopez LF","Ramirez-Estrada K"],"additional_accession":[]},"is_claimable":false,"name":"Metformin May Alter the Metabolic Reprogramming in Cancer Cells by Disrupting the L-Arginine Metabolism: A Preliminary Computational Study.","description":"Metabolic reprogramming in cancer is considered to be one of the most important hallmarks to drive proliferation, angiogenesis, and invasion. AMP-activated protein kinase activation is one of the established mechanisms for metformin's anti-cancer actions. However, it has been suggested that metformin may exert antitumoral effects by the modulation of other master regulators of cellular energy. Here, based on structural and physicochemical criteria, we tested the hypothesis that metformin may act as an antagonist of L-arginine metabolism and other related metabolic pathways. First, we created a database containing different L-arginine-related metabolites and biguanides. After that, comparisons of structural and physicochemical properties were performed employing different cheminformatic too","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-18T11:10:55.686Z","creation":"2025-05-18T11:10:55.686Z"},"accession":"S-EPMC10049129","cross_references":{"pubmed":["36982390"],"doi":["10.3390/ijms24065316"]}}